Xconomy

JANUARY 29, 2019

So this morning the company cut a deal with Neurocrine Biosciences to bankroll the journey—and forfeit some of the financial upside for the product, known as VY-AADC. Neurocrine (NASDAQ: NBIX ) has agreed to pay Voyager (NASDAQ: VYGR ) $115 million in cash and buy $50 million worth of the Cambridge, MA, company’s shares at $11.96

San Diego 108

San Diego Pricing Product Company 108

Xconomy

AUGUST 2, 2019

We’re in the midst of earnings season, and a couple of San Diego’s publicly traded biotechs recently updated investors this week with sales data and other financial insights. Here’s a look at those companies.

Pricing 61

Pricing Sales Company Companies 61

Xconomy

MAY 18, 2018

There’s nothing abstract about a 20 percent jump in a company’s stock price. We also have the latest on the Trump administration’s finger-wagging attempts to rein in drug prices; a raft. It’s even worth asking whether they’re worth writing about at all. Read more » Reprints | Share:

Pricing 62

Pricing Writing Startup San Diego 62

Xconomy

JULY 13, 2018

Drug price changes typically happen either at the start of the calendar year or the beginning of the third quarter. Such changes are routine for many companies, but Pfizer took an unusual step this week by rolling back scheduled price increases on 40 of its drugs. In May, Trump and. Read more » Reprints | Share:

Pricing 56

Pricing Guide News Services 56

Xconomy

JULY 8, 2020

Dave Johnson has known UC San Diego physician and cancer reseacher Thomas Kipps for nearly 20 years.

San Diego 121

San Diego Develop Development UCSD 121

Xconomy

MAY 22, 2020

But the biotech sector is defying the pandemic with crossover financings and freshly minted public companies. On Friday, three firms added their names to the list of life science companies preparing to join the public markets. COVID-19 has ravaged the economy, and it was expected to quash the IPO market, too.

Company 145

Company Companies Marketing Develop 145

Xconomy

JANUARY 10, 2020

Six CEOs, including five who run public companies, co-authored the letter. A letter signed by 215 people involved in the biopharma industry, including CEOs and investors, published Wednesday promised to put the “interests of patients first.”

Pricing 52

Pricing Guide San Diego Company 52

Xconomy

JUNE 26, 2018

When President Trump signed legislation last month allowing seriously ill patients the “right to try” unapproved drugs without FDA oversight, he voiced a bold prediction: Within two weeks, he said, drug companies would announce “voluntary massive drops in prices.” Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 55

Pricing Services San Diego Company 55

Xconomy

JANUARY 31, 2019

The company initially filed for an IPO as activity at the SEC ground to a halt during the partial federal government shutdown. Gossamer Bio is dropping its plan to pursue a little-used path to the public markets and will instead return to a conventional IPO that is reviewed by securities regulators.

San Diego 71

San Diego Pricing Activity Marketing 71

Xconomy

OCTOBER 17, 2017

In advance of an anticipated Senate hearing on drug prices, President Donald Trump once again denounced drug companies as “getting away with murder.” He also said at the time that “we’re going to start bidding,” a reference to Medicare’s inability to negotiate drug prices.

Pricing 56

Pricing Startup Marketing San Diego 56

Xconomy

JULY 31, 2020

If you’ve never heard of Arya (NASDAQ: ARYBU ), it’s a shell company that Perceptive Advisors formed specifically to serve as a vehicle to take a private company public. This week the neuroscience drug developer reached a deal to merge with publicly traded Arya Sciences Acquisition Corp II. Cerevel is young, but it’s pretty far along.

Pricing 72

Pricing Acquisition Capital Marketing 72

Xconomy

SEPTEMBER 19, 2016

Amid the hue and cry over the Mylan EpiPen pricing debacle , Hillary Clinton unveiled her “ Plan to Respond to Unjustified Price Hikes for Long-Available Drugs. ” Clinton’s plan calls for “dedicated oversight to protect consumers.” That dependence on price increases won’t change any time soon.

Pricing 40

Pricing Competition Blogging Journal 40

Xconomy

APRIL 17, 2019

Turning Point Therapeutics raised more than $166 million in its IPO, pricing at the top of its range and putting nearly 2 million more shares into the public markets than it had initially planned. million shares at $18 apiece, raising $166.5 million before discounts, commissions, and offering expenses.

Pricing 57

Pricing Demand Marketing Develop 57

Xconomy

APRIL 26, 2019

Biopharmaceutical companies don’t like to talk about the failures. Biogen’s (NASDAQ: BIIB ) earnings call this week was the first since its Alzheimer’s drug aducanumab failed in a Phase 3 study and eviscerated the company’s shares. The road to every new drug approval is littered with the remains of earlier failures.

News 94

News Pricing Study Company 94

Xconomy

AUGUST 17, 2018

Both were landmarks for the companies receiving the nod, Alnylam Pharmaceuticals and Amicus Therapeutics. We also saw a new biotech emerge in the muggy New York heat, a couple deals for new flu vaccines, and interesting developments in the complicated world of drug pricing. It’s hot out there.

Pricing 52

Pricing Venture Capital Develop Development 52

Xconomy

NOVEMBER 19, 2018

The San Diego-based biotech set a preliminary $100 million target for its IPO in documents filed with securities regulators Friday. That figure will change as the company determines how many shares it will sell and at what price. Cibus has applied for a listing on the Nasdaq exchange under the stock symbol “CBUS.”

San Diego 72

San Diego Research Startup Pricing 72

Xconomy

JULY 14, 2017

Akcea Therapeutics is joining the parade of biotechs going public, but the company had to cut its stock price and sell more shares in order to pull it off. But the biotech priced its offering of 15.6 million shares at $8 apiece, well below the $12 to $14 per share range that the company had initially set for an offering of 9.6

Pricing 57

Pricing Company Companies San Diego 57

Xconomy

OCTOBER 26, 2018

As with another Alzheimer’s meeting back in July , much of the interest there focused on data from a drug developed by Japanese pharmaceutical company Eisai and partner Biogen that has left. Also this week, the Clinical Trials on Alzheimer’s Disease conference took place in Barcelona, Spain. Read more » Reprints | Share:

Pricing 86

Pricing Conference Research Invest 86

Xconomy

JULY 29, 2020

Thrive Earlier Detection, one of the companies vying to be the first to commercialize a blood test that can uncover cases of cancer before symptoms arise, has raised $257 million and announced plans to evaluate its CancerSEEK test in a registrational study. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

San Diego 87

San Diego Study Capital Invest 87

Xconomy

FEBRUARY 4, 2019

Battery-technology business Maxwell Technologies has agreed to be acquired by Silicon Valley electric car company Tesla (NASDAQ: TSLA ) in an all-stock deal valued at about $218 million, the San Diego-based company announced Monday. apiece, a 55 percent premium over its stock price as of market close Feb.

Technology 46

Technology San Diego Pricing News 46

Xconomy

APRIL 13, 2017

San Diego-based Tocagen (NASDAQ: TOCA ) priced its offering of 8.5 The company had previously planned to sell 7.25 million shares priced between $10 to $12 each. Tocagen has been developing a gene therapy treatment for a deadly type of brain cancer. million shares at $10 per share.

San Diego 66

San Diego Pricing Demand Marketing 66

Xconomy

DECEMBER 18, 2018

Seismic, an enterprise software company with ambitious growth plans, has raised $100 million in a Series E financing and added Microsoft chairman John W. The venture investment, which the San Diego startup announced Tuesday, is one of only a few so-called mega-rounds—$100 million or more—recorded this year in the region.

Southern California 110

Southern California San Diego Software Invest 110

Xconomy

DECEMBER 10, 2018

ASG Technologies, the Florida-based software company backed by activist hedge fund Elliott Management, has upped its offer for San Diego’s Mitek Systems to $11.50 26 letter the Florida-based software company made public Monday. The stock price of Mitek (NASDAQ:MITK) rose nearly 9 percent on the news, closing at $9.75.

Pricing 43

Pricing Acquisition News Software 43

Xconomy

SEPTEMBER 6, 2019

Being first to market with a new type of drug brings advantages. The first mover sets the bar for what physicians, payers, and patients can expect of that medicine and how much it costs. It grabs market share that followers have to steal away. But the first mover isn’t infallible if someone else has something better. is counting on.

Pricing 84

Pricing Class Study Marketing 84

Xconomy

MARCH 10, 2017

The San Diego-based biotech filed the paperwork Thursday for an IPO that could raise up to $86 million—a figure likely to change as the company determines how many shares it will sell, and at what price. Tocagen has applied to the Nasdaq Exchange for a listing under the stock symbol “TOCA.”

San Diego 79

San Diego Pricing Southern California Develop 79

Xconomy

FEBRUARY 12, 2019

But the party might be coming to an end, according to Jim Greenwood, the head of the Biotechnology Innovation Organization, one of two major trade groups representing biopharmaceutical companies. These are dangerous times,” Greenwood said during a panel discussion at the BIO CEO.

Pricing 79

Pricing Organization San Diego Company 79

Xconomy

APRIL 23, 2019

As public backlash against high drug prices shows no signs of waning, a private nonprofit in Boston, the Institute for Clinical Economic Review (ICER), has emerged as the country’s top drug-pricing watchdog. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 104

Pricing Report Funding San Diego 104

Xconomy

JANUARY 11, 2017

On the campaign trail and as president-elect he has made occasional noises about drug pricing—giving the U.S. Medicare system, the largest buyer of drugs in the world, the right to negotiate prices, for instance. He said drug companies are “getting away with murder” because of the prices they charge.

Company 40

Company Companies Pricing Press 40

Xconomy

MARCH 12, 2018

Her out-of-pocket costs were pretty reasonable until two years ago, she says, when she had to switch insurance companies. For 20 years, Deborah Long (pictured) has been relying on powerful drugs to keep her multiple sclerosis in check. Her new insurer made her switch to a different drug, Copaxone.

Pricing 71

Pricing San Diego Company Companies 71

Xconomy

NOVEMBER 26, 2019

The company said an interim analysis showed no benefit compared to the placebo. On the same day the company said CEO George Tidmarsh had left “to pursue other interests,” and that a search for a new chief executive was underway.

Pricing 63

Pricing Study Product San Diego 63

Xconomy

JANUARY 31, 2020

million more shares than anticipated and pricing at the high end of its planned range. The stock price closed at $21.80, up 28 percent. The company joins the public markets with four product candidates in its pipeline, all topical non-steroidal treatments being developed for seven dermatological indications.

Westlake Village 114

Westlake Village Pricing Develop Development 114

Xconomy

NOVEMBER 3, 2016

We’re talking of course about next week’s vote on Proposition 61 in California, an attempt to control drug prices in the nation’s most populous state. million), are all drug companies. First, the prices negotiated by the VA are secret. They start with a discounted price list, but can go down from there.

Company 40

Company Companies Pricing Slides 40

Xconomy

AUGUST 15, 2019

TuSimple, an autonomous trucking company, has been conducting test drives for UPS between the Arizona cities of Phoenix and Tucson since May.

San Diego 79

San Diego Startup Technology Company 79

Xconomy

JANUARY 13, 2017

The incoming party-pooper-in-chief, Donald Trump, said during his first press conference Wednesday that drug companies are “ getting away with murder ” and he’d work to rein in prices and other practices. You could hear the needle screeeeeeeeching across the vinyl. Good thing it came Wednesday; Tuesday is the.

Pricing 40

Pricing Conference Press Report 40

Xconomy

AUGUST 31, 2020

Akcea Therapeutics is returning to its parent company, Ionis Pharmaceuticals, in a $500 million deal that brings an end to a tumultuous three years as a standalone company. That price is a 60 percent premium to the Boston-based company’s closing stock price on Friday. Akcea develops drugs for rare diseases.

Pricing 89

Pricing Product Develop Development 89

Xconomy

JUNE 16, 2016

In San Diego, the complaints often focus on the relative scarcity of venture capital and hometown VC firms. So when the San Diego Venture Group recruited Mark Suster of Los Angeles-based Upfront Ventures to give the keynote talk Tuesday night for Startup Week San Diego, more than 800 people filled a downtown auditorium.

Venture Capital 49

Venture Capital San Diego Truecar Web 49

Xconomy

OCTOBER 6, 2016

San Diego’s Brain Corp. Before getting out on the open road, however, the company wants to show its self-driving system can clean up a mess in aisle 3 at Jimbo’s. The company actually has been test-driving its technology on floor scrubbers used to clean Jimbo’s, a San Diego natural foods grocer. “We

Product 106

Product Artificial Inteligence San Diego Training 106